The abstract is read at the publisher; the summary is JClub's.
ADORA1-FASN–palmitic acid metabolic reprogramming is linked to therapy-induced senescence and oxaliplatin resistance in colorectal cancer, with ADORA1 induced by oxaliplatin and enriched in chemoresistant patients.
- Why it matters: Early acquired resistance to oxaliplatin-based neoadjuvant chemotherapy limits benefit in locally advanced colorectal cancer, and the senescence programs driving that resistance were unclear.
- What they did: CRC cells and xenograft models exposed to oxaliplatin showed TIS-like senescence marker upregulation, and senolytic ABT263 reduced senescence and restored oxaliplatin sensitivity; RNA-seq integration implicated ADORA1, which was tested via knockdown and ADORA1–FASN interaction/stabilization assays.
- The result: ADORA1 directly interacts with and stabilises FASN, promoting palmitic acid synthesis, lipid droplet accumulation, and p53/p21-driven senescence; ADORA1 knockdown attenuated these phenotypes and restored oxaliplatin sensitivity, identifying ADORA1–FASN–PA as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.